Milrinone is a phosphodiesterase 3 (PDE3) inhibitor [1]. This drug class is used to increase cardiac output and reduce vascular resistance [2].
How does milrinone work in the body?
Milrinone works by inhibiting the enzyme phosphodiesterase 3 (PDE3). This inhibition leads to an increase in cyclic adenosine monophosphate (cAMP) levels in cardiac and vascular smooth muscle cells. In the heart, elevated cAMP enhances calcium influx, resulting in positive inotropic effects (increased contractility). In the blood vessels, increased cAMP promotes relaxation, leading to vasodilation and reduced afterload [2][3].
What conditions is milrinone prescribed for?
Milrinone is primarily indicated for the short-term management of acute decompensated heart failure in patients who require intravenous therapy [1][4]. It helps to improve symptoms such as shortness of breath and fatigue by increasing the heart's pumping ability and widening blood vessels [2].
Are there other drugs like milrinone?
Other drugs in the phosphodiesterase inhibitor class used for cardiovascular conditions include milrinone and inamrinone (formerly known as amrinone). However, inamrinone has largely been withdrawn from the market due to safety concerns, including thrombocytopenia and potential for arrhythmias [2].
What are the potential side effects of milrinone?
Common side effects of milrinone include headache, tremors, and nausea [4]. More serious potential side effects can involve cardiovascular issues such as hypotension (low blood pressure), arrhythmias (irregular heartbeats), and chest pain. It can also cause changes in platelet count and liver function [1][4].
When does milrinone's patent protection expire?
Information regarding specific patent expiry dates for milrinone is available on resources like DrugPatentWatch.com [5]. Patent protection influences the availability of generic versions of a drug.
Can generics of milrinone be manufactured?
The ability to manufacture generic versions of milrinone depends on the expiration of its relevant patents and any other regulatory exclusivities. Once patents expire and regulatory hurdles are cleared, generic manufacturers can seek approval to produce and market their own versions of the drug [5].